Kyrgyzstan Medical Device Registration Prerequisites: Market Confirmation and Positive Expert Evaluation

1. Key takeaways

The law establishes two prerequisites for state registration of devices in Kyrgyzstan: first, confirmation that the product has been circulated as a medical device in the manufacturing country or in other countries; second, a positive expert evaluation of safety, quality and effectiveness, taking into account the potential risk level of use. Both requirements are set out in Article 14 of Law No. 216 and are restated verbatim by the competent authority on its website. Understanding these two requirements explains why the basic rhythm of this market is that a third-party approval comes first, and the Kyrgyz registration comes after.

2. Legal basis

1. Law of the Kyrgyz Republic On the Circulation of Medical Devices, No. 216 of December 29, 2023, Article 14: foreign products must have confirmation of circulation as a medical device in the manufacturing country or in other countries, and must obtain a positive expert evaluation of safety, quality and effectiveness taking into account the potential risk level of use.
2. Public information of the competent authority (the Department of Medicines and Medical Products of the Ministry of Health) in the medical device section of its website, published in Russian and Kyrgyz: state registration applies to medical devices that have been confirmed to circulate as medical devices in the manufacturing country or in other countries and have obtained a positive expert evaluation of safety, quality and effectiveness taking into account the potential risk level.
3. Cabinet Resolution No. 513 of August 27, 2024, Annex 1: procedures for state registration and assessment of safety, quality and effectiveness.
4. Published form Annex 10 of the competent authority: the declaration by the applicant of responsibility for the truthfulness of the information and documents submitted.

3. Expert insights

Insight 1: the first prerequisite turns the free sale certificate into a hard threshold.

What the law requires is confirmation of circulation as a medical device in the manufacturing country or in other countries. For Chinese manufacturers, this requirement is in practice met through a free sale certificate or a certificate of registration in the country of origin. There are three pitfalls here:

• Issuing body: the document must be issued by the competent authority of the manufacturing country; documents from industry associations or third-party organizations are usually not accepted;
• Content elements: the document must show that the product circulates as a medical device; a document that only shows a quality management system certificate or only export activity does not satisfy the requirement;
• Validity and consistency: the models, specifications, and the name and address of the manufacturer stated in the document must match the registration dossier exactly.

Insight 2: the second prerequisite shows that Kyrgyzstan is an evaluation system, not a filing system.

A positive expert evaluation means the competent authority makes a substantive judgment on safety, quality and effectiveness rather than merely registering the file once documents are complete. This is fundamentally different from the notifiable filing systems of some markets. The depth of the evaluation is modulated by the risk class — the higher the class, the deeper the evaluation and the thicker the evidence required. It is therefore more accurate to read the second prerequisite as risk-stratified evidence requirements than as a single fixed review.

Insight 3: combining the two prerequisites produces the economic logic of the eight-country simplified pathway.

In the draft amendments published for public comment by the competent authority in 2026, for devices already holding registration documents in the EU, Australia, the United Kingdom, Canada, the United States, Switzerland, Norway or Japan, the registration timeline would be compressed from the current maximum of 30 calendar days to 10 working days (draft status, not yet in force; see Article 13 of this series). The underlying logic is exactly this: if the first prerequisite (confirmation of circulation elsewhere) and the second prerequisite (evaluation of safety, quality and effectiveness) have already been substantially completed through one of the eight approvals, the domestic evaluation workload can naturally be reduced. Understanding this layer allows a prediction: the stronger the third-party approval in hand, the lower the time cost in Kyrgyzstan.

Insight 4: the Annex 10 responsibility declaration is the backstop clause for both prerequisites.

The competent authority requires the applicant to sign the declaration of responsibility for the truthfulness of the information and documents submitted (published form Annex 10). This declaration closes the loop with Article 15 of Law No. 216, under which the provision of false information constitutes a ground for revocation of the registration certificate. The consequence of unmet prerequisites is not only rejection, but possible revocation after approval.

4. Practical recommendations

First, schedule the free sale certificate at the very front of the project. Obtaining a free sale certificate for foreign registration purposes takes time for Chinese manufacturers, and the document must state circulation as a medical device. We recommend starting it immediately after the classification justification is completed, not after the dossier has been written.

Second, run an inventory of approval assets before deciding the pathway. At project initiation, list all foreign approvals held by the company: China NMPA, EU CE, US FDA, Japan PMDA, and other national approvals. If a currently valid approval from one of the eight countries is already held, the availability of the simplified pathway can materially change the time and budget structure of the project.

Third, prepare a stratified evidence package for the second prerequisite, by risk class:

• Class 1: technical requirements, declaration of conformity, basic performance data;
• Class 2a: the above plus biological effects evaluation where applicable, plus sterilization validation for sterile products;
• Class 2b: the above plus technical test reports plus clinical evaluation;
• Class 3: the above plus full clinical evidence plus cooperation with production site inspection.

Fourth, ensure that translations of all foreign-language documents correspond to the originals item by item. Translation errors in prerequisite documents are a frequent cause of deficiency letters at the acceptance stage. We recommend using translators with a medical device regulatory background and having the authorized representative review the translations.

5. Verification checklist

• □ A confirmation of circulation issued by the competent authority of the manufacturing country (free sale certificate or equivalent) has been obtained, stating circulation as a medical device;
• □ The models, specifications, and the name and address of the manufacturer in that document match the registration dossier exactly;
• □ The approval asset inventory has been completed, confirming whether a currently valid registration document is held in one of the eight jurisdictions: the EU, Australia, the United Kingdom, Canada, the United States, Switzerland, Norway or Japan;
• □ A stratified evidence package has been prepared according to the risk class;
• □ Published form Annex 10, the declaration of responsibility for the truthfulness of information, has been signed by a person with signing authority, consistent with the power of attorney;
• □ Russian and Kyrgyz translations of all foreign-language documents have been completed and reviewed by the authorized representative.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, production site inspection coordination, quality management system conformity support, post-market surveillance and device vigilance system setup, import and distribution compliance, official fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for the issues foreign manufacturers most often encounter in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are always marked as practical estimates, and experience-based values are never presented as legal requirements.

GRZAN provides registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives. For project consultation on Kyrgyzstan or Eurasian Economic Union market access, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services